Moving forward, Roche is prioritizing and reimagining its R&D strategy to build a stronger portfolio.
Tag Archive for: Hemlibra
A U.S. federal court upheld a prior ruling in favor of Roche’s Genentech, finding that its blockbuster hemophilia treatment Hemlibra did not infringe on patent protections held by Takeda’s Baxalta.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.
